Organised by the FIP Technology Advisory Group in collaboration with the FIP Industrial Pharmacy Section & the FIP Early Career Pharmaceutical Group
Chair(s)
Dr Matthew Cherian, ExCo Member Industrial Pharmacy Section & Dr Claudia Rijcken, Member FIP Technology Advisory Group, Netherlands
Introduction:
This session will explore the transformative impact of AI in various stages of the drug development lifecycle and the unique role pharmaceutical researchers play in leveraging this technology. By focusing on drug discovery, research and clinical development, we aim to inspire researchers to use AI tools in these roles to enhance their output and efficiency. The session will provide insights into the integration of AI in various R&D processes, and encourage attendees to consider the potential of AI in their own work.
Programme:
| 14:30 – 14:35 | Introduction by the chairs |
| 14:35 – 14:55 | Artificial intelligence in drug discovery and research (educational/academic perspective) |
| Speaker to be confirmed | |
| 14:55 – 15:15 | AI-powered drug discovery: faster hits, better PK, lower costs |
| Dr Olivier Mailhot, Université de Montréal, Canada | |
| 15:15 – 15:55 | Panel discussion |
| 15:55 – 16:00 | Wrap-up by chairs |
Learning objectives:
1. To articulate how pharmaceutical researchers can contribute to AI applications in the early stages of drug discovery, including molecular design and toxicity prediction. This understanding will enable pharmacists to actively engage in AI-augmented drug design processes and provide valuable insights into optimising these technologies for safe and effective drug development.
2. To evaluate and implement AI-driven methodologies that improve patient selection, optimise clinical protocols, and predict treatment outcomes. This objective will empower pharmaceutical researchers to apply their clinical knowledge to AI models, enhancing the relevance and accuracy of AI in clinical settings and promoting safer, more personalised treatments.
3. To understand how AI has transformed the R&D process already, and the future opportunities that lie ahead of us.
Take home messages:
AI has already improved the cost-effectiveness of drug discovery, research and development.
Pharmaceutical researchers can play a significant role in harnessing AI for safer, smarter drug discovery.
AI-driven insights in clinical trials empower pharmaceutical researchers to enhance patient outcomes.
FIP Development Goals:
Please see below the FIP Development Goals related to the session.
FIP Development Goal 5: Competency Development
FIP Development Goal 7: Advancing Integrated Services
FIP Development Goal 11: Impact and Outcomes
FIP Development Goal 18: Access to Medicines, Devices & Services
FIP Development Goal 21: Sustainability in Pharmacy
